News
SRNE
0.0033
+3.13%
0.0001
Weekly Report: what happened at SRNE last week (1007-1011)?
Weekly Report · 3d ago
Weekly Report: what happened at SRNE last week (0930-1004)?
Weekly Report · 10/07 11:20
Weekly Report: what happened at SRNE last week (0923-0927)?
Weekly Report · 09/30 11:13
Weekly Report: what happened at SRNE last week (0916-0920)?
Weekly Report · 09/23 11:12
Weekly Report: what happened at SRNE last week (0909-0913)?
Weekly Report · 09/16 11:03
Weekly Report: what happened at SRNE last week (0902-0906)?
Weekly Report · 09/09 11:13
Weekly Report: what happened at SRNE last week (0826-0830)?
Weekly Report · 09/02 11:16
Weekly Report: what happened at SRNE last week (0819-0823)?
Weekly Report · 08/26 11:14
Healthcare bankruptcies slow after peaking in 2023: report
Seeking Alpha · 08/24 15:25
Weekly Report: what happened at SRNE last week (0812-0816)?
Weekly Report · 08/19 11:01
Weekly Report: what happened at SRNE last week (0805-0809)?
Weekly Report · 08/12 11:04
Weekly Report: what happened at SRNE last week (0729-0802)?
Weekly Report · 08/05 11:14
Weekly Report: what happened at SRNE last week (0722-0726)?
Weekly Report · 07/29 11:04
Weekly Report: what happened at SRNE last week (0715-0719)?
Weekly Report · 07/22 11:05
Weekly Report: what happened at SRNE last week (0708-0712)?
Weekly Report · 07/15 11:02
Weekly Report: what happened at SRNE last week (0701-0705)?
Weekly Report · 07/08 11:03
Weekly Report: what happened at SRNE last week (0624-0628)?
Weekly Report · 07/01 11:04
Weekly Report: what happened at SRNE last week (0617-0621)?
Weekly Report · 06/24 11:11
Weekly Report: what happened at SRNE last week (0610-0614)?
Weekly Report · 06/17 11:02
Weekly Report: what happened at SRNE last week (0603-0607)?
Weekly Report · 06/10 11:04
More
Webull provides a variety of real-time SRNE stock news. You can receive the latest news about Sorrento Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRNE
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.